Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions

Human Gene Therapy

Volumn 23, Issue 5, 2012, Pages 492-507

  Naumer, Matthias ^a   Ying, Ying ^b   Michelfelder, Stefan ^c   Reuter, Antje ^d   Trepel, Martin ^c   Müller, Oliver J ^e   Kleinschmidt, Jürgen A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Shenzhen University   (China)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; LUCIFERASE;

ADENOVIRUS 2; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL ISOLATION; COMBINATORIAL LIBRARY; CORONARY ARTERY; ENDOTHELIUM CELL; GENE INSERTION; GENETIC TRANSDUCTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE LIBRARY; RAT; TUMOR CELL; VIRUS CAPSID; VIRUS PARTICLE;

ANIMALS; BINDING SITES; CAPSID PROTEINS; CELL LINE, TUMOR; DEPENDOVIRUS; ENDOTHELIAL CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; MUTAGENESIS, INSERTIONAL; MYOBLASTS, CARDIAC; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; RATS; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS - 2; MIRIDAE; RATTUS;

EID: 84861667857     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.139     Document Type: Article

References (69)

1. Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97-106. (Pubitemid 43922139)
2. Asokan, A., Hamra, J.B., Govindasamy, L., et al. (2006). Adenoassociated virus type 2 contains an integrin a5b1 binding domain essential for viral cell entry. J. Virol. 80, 8961-8969. (Pubitemid 44359970)
3. Atchison, R.W., Casto, B.C., and Hammon, W.M. (1965). Adenovirus-associated defective virus particles. Science 149, 754-756.
4. Bantel-Schaal, U., and zur Hausen, H. (1984). Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology 134, 52-63. (Pubitemid 14138922)
5. Bartlett, J.S., Kleinschmidt, J., Boucher, R.C., and Samulski, R.J. (1999). Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'c)2 antibody. Nat. Biotechnol. 17, 181-186. (Pubitemid 29072544)
6. Boucas, J., Lux, K., Huber, A., et al. (2009). Engineering adenoassociated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations. J. Gene Med. 11, 1103-1113.
7. Brown, B.D., Venneri, M.A., Zingale, A., et al. (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12, 585-591.
8. Carter, B.J. (2005). Adeno-associated virus vectors in clinical trials. Hum. Gene Ther. 16, 541-550. (Pubitemid 40740922)
9. Choi, V.W., McCarty, D.M., and Samulski, R.J. (2005). AAV hybrid serotypes: improved vectors for gene delivery. Curr. Gene Ther. 5, 299-310. (Pubitemid 40895014)
10. Daya, S., and Berns, K.I. (2008). Gene therapy using adenoassociated virus vectors. Clin. Microbiol. Rev. 21, 583-593.
11. Di Pasquale, G., Davidson, B.L., Stein, C.S., et al. (2003). Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9, 1306-1312. (Pubitemid 37279855)
12. Du, B., Wu, P., Boldt-Houle, D.M., and Terwilliger, E.F. (1996). Efficient transduction of human neurons with an adenoassociated virus vector. Gene Ther. 3, 254-261. (Pubitemid 26120427)
13. Dubielzig, R., King, J.A., Weger, S., et al. (1999). Adenoassociated virus type 2 protein interactions: formation of preencapsidation complexes. J. Virol. 73, 8989-8998. (Pubitemid 29487052)
14. Gao, G., Vandenberghe, L.H., Alvira, M.R., et al. (2004). Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381-6388. (Pubitemid 38715936)
15. Gao, G., Vandenberghe, L.H., and Wilson, J.M. (2005). New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285-297. (Pubitemid 40895013)
16. Gao, G.P., Alvira, M.R., Wang, L., et al. (2002). Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859. (Pubitemid 34994488)
17. Gigout, L., Rebollo, P., Clement, M., et al. (2005). Altering AAV tropism with mosaic viral capsids. Mol. Ther. 11, 856-865. (Pubitemid 40724104)
18. Girod, A., Ried, M., Wobus, C., et al. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 5, 1052-1056. (Pubitemid 29439578)
19. Grifman, M., Trepel, M., Speece, P., et al. (2001). Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964-975. (Pubitemid 32611306)
20. Grimm, D., Kern, A., Pawlita, M., et al. (1999). Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6, 1322-1330. (Pubitemid 29359028)
21. Grimm, D., Kay, M.A., and Kleinschmidt, J.A. (2003). Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7, 839-850. (Pubitemid 36790261)
22. Grimm, D., Lee, J.S., Wang, L., et al. (2008). In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82, 5887-5911. (Pubitemid 351822263)
23. Hauswirth, W.W., Lewin, A.S., Zolotukhin, S., and Muzyczka, N. (2000). Production and purification of recombinant adenoassociated virus. Methods Enzymol. 316, 743-761. (Pubitemid 30235704)
24. Hoggan, M.D., Blacklow, N.R., and Rowe, W.P. (1966). Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc. Natl. Acad. Sci. U.S.A. 55, 1467-1474.
25. Kaplitt, M.G., Leone, P., Samulski, R.J., et al. (1994). Long-term gene expression and phenotypic correction using adenoassociated virus vectors in the mammalian brain. Nat. Genet. 8, 148-154. (Pubitemid 24308362)
26. Kern, A., Schmidt, K., Leder, C., et al. (2003). Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77, 11072-11081. (Pubitemid 37204297)
27. Koeberl, D.D., Alexander, I.E., Halbert, C., et al. (1997). Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc. Natl. Acad. Sci. U.S.A.94, 1426-1431. (Pubitemid 27087867)
28. Koerber, J.T., Jang, J.H., and Schaffer, D.V. (2008). DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 16, 1703-1709.
29. Li, W., Asokan, A., Wu, Z., et al. (2008). Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16, 1252-1260. (Pubitemid 351866056)
30. Lochrie, M.A., Tatsuno, G.P., Christie, B., et al. (2006). Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 80, 821-834. (Pubitemid 43062894)
31. Loiler, S.A., Conlon, T.J., Song, S., et al. (2003). Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther. 10, 1551-1558. (Pubitemid 37063260)
32. Maheshri, N., Koerber, J.T., Kaspar, B.K., and Schaffer, D.V. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204. (Pubitemid 43221704)
33. McCarty, D.M., Young, S.M., Jr., and Samulski, R.J. (2004). Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38, 819-845. (Pubitemid 40013747)
34. McCown, T.J., Xiao, X., Li, J., et al. (1996). Differential and persistent expression patterns of CNS gene transfer by an adenoassociated virus (AAV) vector. Brain Res. 713, 99-107. (Pubitemid 26114833)
35. Michelfelder, S., and Trepel, M. (2009). Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet. 67, 29-60.
36. Michelfelder, S., Lee, M.K., deLima-Hahn, E., et al. (2007). Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp. Hematol. 35, 1766-1776. (Pubitemid 350117116)
37. Michelfelder, S., Kohlschü tter, J., Skorupa, A., et al. (2009). Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 4, e5122.
38. Mitchell, A.M., Nicolson, S.C., Warischalk, J.K., and Samulski, R.J. (2010). AAV's anatomy: roadmap for optimizing vectors for translational success. Curr. Gene Ther. 10, 319-340.
39. Mori, S., Wang, L., Takeuchi, T., and Kanda, T. (2004). Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330, 375-383. (Pubitemid 39572844)
40. Mueller, C., and Flotte, T.R. (2008). Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 15, 858-863. (Pubitemid 351712619)
41. Mü ller, O.J., Kaul, F., Weitzman, M.D., et al. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21, 1040-1046. (Pubitemid 37064733)
42. Mü ller, O.J., Leuchs, B., Pfleger, S.T., et al. (2006). Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc. Res. 70, 70-78.
43. Muzyczka, N., and Warrington, K.H., Jr. (2005). Custom adenoassociated virus capsids: the next generation of recombinant vectors with novel tropism. Hum. Gene Ther. 16, 408-416. (Pubitemid 40647138)
44. Nakai, H., Wu, X., Fuess, S., et al. (2005). Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J. Virol. 79, 3606-3614. (Pubitemid 40327949)
45. Nayak, S., and Herzog, R.W. (2010). Progress and prospects: immune responses to viral vectors. Gene Ther. 17, 295-304.
46. Nicklin, S.A., Buening, H., Dishart, K.L., et al. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174-181. (Pubitemid 32851280)
47. Opie, S.R., Warrington, K.H., Jr., Agbandje-McKenna, M., et al. (2003). Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995-7006. (Pubitemid 36666892)
48. Parks, W.P., Green, M., Piñ a, M., and Melnick, J.L. (1967). Physicochemical characterization of adeno-associated satellite virus type 4 and its nucleic acid. J. Virol. 1, 980-987.
49. Paull, K.D., Shoemaker, R.H., Hodes, L., et al. (1989). Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81, 1088-1092. (Pubitemid 19175145)
50. Perabo, L., Bü ning, H., Kofler, D.M., et al. (2003). In vitro selection of viral vectors with modified tropism: the adenoassociated virus display. Mol. Ther. 8, 151-157. (Pubitemid 36939306)
51. Ponnazhagan, S., Mahendra, G., Kumar, S., et al. (2002). Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J. Virol. 76, 12900-12907. (Pubitemid 35386973)
52. Rabinowitz, J.E., Bowles, D.E., Faust, S.M., et al. (2004). Crossdressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J. Virol. 78, 4421-4432. (Pubitemid 38501062)
53. Ross, D.T., Scherf, U., Eisen, M.B., et al. (2000). Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227-235. (Pubitemid 30132189)
54. Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309-319. (Pubitemid 28048842)
55. Schmidt, M., Govindasamy, L., Afione, S., et al. (2008a). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911-8916.
56. Schmidt, M., Voutetakis, A., Afione, S., et al. (2008b). Adenoassociated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399-1406.
57. Sun, J.Y., Anand-Jawa, V., Chatterjee, S., and Wong, K.K. (2003). Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther. 10, 964-976. (Pubitemid 36722431)
58. Veldwijk, M.R., Topaly, J., Laufs, S., et al. (2002). Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther. 6, 272-278. (Pubitemid 36336136)
59. Verma, I.M., and Weitzman, M.D. (2005). Gene therapy: twentyfirst century medicine. Annu. Rev. Biochem. 74, 711-738. (Pubitemid 40995522)
60. Warrington, K.H., Jr., and Herzog, R.W. (2006). Treatment of human disease by adeno-associated viral gene transfer. Hum. Genet. 119, 571-603. (Pubitemid 43805835)
61. Waterkamp, D.A., Mü ller, O.J., Ying, Y., et al. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307-1319. (Pubitemid 44782510)
62. Work, L.M., Nicklin, S.A., Brain, N.J., et al. (2004). Development of efficient viral vectors selective for vascular smooth muscle cells. Mol. Ther. 9, 198-208. (Pubitemid 38256546)
63. Work, L.M., Bü ning, H., Hunt, E., et al. (2006). Vascular bedtargeted in vivo gene delivery using tropism-modified adenoassociated viruses. Mol. Ther. 13, 683-693.
64. Wu, P., Xiao, W., Conlon, T., et al. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647. (Pubitemid 30666714)
65. Wu, Z., Asokan, A., and Samulski, R.J. (2006). Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14, 316-327. (Pubitemid 44184972)
66. Xie, Q., Bu, W., Bhatia, S., et al. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 10405-10410.
67. Ying, Y., Mü ller, O.J., Goehringer, C., et al. (2010). Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther. 17, 980-990.
68. Zaiss, A.K., and Muruve, D.A. (2008). Immunity to adenoassociated virus vectors in animals and humans: a continued challenge. Gene Ther. 15, 808-816. (Pubitemid 351712613)
69. Zolotukhin, S., Potter, M., Hauswirth, W.W., et al. (1996). A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. Virol. 70, 4646-4654.